{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:49:27Z","timestamp":1791229767180,"version":"4.1.0"},"reference-count":55,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2005,12,1]],"date-time":"2005-12-01T00:00:00Z","timestamp":1133395200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of the American Dental Association"],"published-print":{"date-parts":[[2005,12]]},"DOI":"10.14219\/jada.archive.2005.0108","type":"journal-article","created":{"date-parts":[[2014,1,8]],"date-time":"2014-01-08T23:36:58Z","timestamp":1389224218000},"page":"1658-1668","source":"Crossref","is-referenced-by-count":323,"title":["Managing the care of patients with bisphosphonate-associated osteonecrosis"],"prefix":"10.1016","volume":"136","author":[{"given":"CESAR A.","family":"MIGLIORATI","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JEFFREY","family":"CASIGLIA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JOEL","family":"EPSTEIN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"PETER L.","family":"JACOBSEN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MICHAEL A.","family":"SIEGEL","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SOOK-BIN","family":"WOO","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.14219\/jada.archive.2005.0108_bib1","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/0278-2391(87)90399-5","article-title":"Osteoradionecrosis: clinical experience and a proposal for classification","volume":"45","author":"Epstein","year":"1987","journal-title":"J Oral Maxillofac Surg"},{"key":"10.14219\/jada.archive.2005.0108_bib2","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/hed.2890100108","article-title":"Osteonecrosis: study of the relationship of dental extractions in patients receiving radiotherapy","volume":"10","author":"Epstein","year":"1987","journal-title":"Head Neck Surg"},{"issue":"supplement 8","key":"10.14219\/jada.archive.2005.0108_bib3","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1652::AID-CNCR15>3.0.CO;2-Z","article-title":"Overview of bisphosphonates","volume":"80","author":"Rogers","year":"1997","journal-title":"Cancer"},{"issue":"supplement 2","key":"10.14219\/jada.archive.2005.0108_bib4","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/jbmr.5650140212","article-title":"The pharmacology of bisphosphonates and new insights into their mechanisms of action","volume":"14","author":"Russell","year":"1999","journal-title":"J Bone Miner Res"},{"key":"10.14219\/jada.archive.2005.0108_bib5","first-page":"18","article-title":"Pharmacokinetics of alendronate: an overview","volume":"101","author":"Lin","year":"1999","journal-title":"Int J Clin Pract Suppl"},{"key":"10.14219\/jada.archive.2005.0108_bib6","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1345\/aph.1E357","article-title":"Discovery, clinical development, and therapeutic uses of bisphosphonates","volume":"39","author":"Licata","year":"2005","journal-title":"Ann Pharmacother"},{"issue":"1","key":"10.14219\/jada.archive.2005.0108_bib7","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/bcr414","article-title":"Development of bisphosphonates","volume":"4","author":"Fleisch","year":"2002","journal-title":"Breast Cancer Res"},{"key":"10.14219\/jada.archive.2005.0108_bib8","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1210\/jc.2005-0057","article-title":"Long-term safety of bisphosphonates","volume":"90","author":"Ott","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.14219\/jada.archive.2005.0108_bib9","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1172\/JCI115539","article-title":"Bisphosphonate action: alendronate localization in rat bone and effects on osteoblast ultrastructure","volume":"88","author":"Sato","year":"1991","journal-title":"J Clin Invest"},{"key":"10.14219\/jada.archive.2005.0108_bib10","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.bbrc.2004.11.072","article-title":"Regulation of apoptosis in osteoclasts and osteoblastic cells","volume":"328","author":"Xing","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"key":"10.14219\/jada.archive.2005.0108_bib11","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.bone.2004.11.013","article-title":"Bisphosphonate (YM529) delays the repair of cortical bone defect after drill-hole injury by reducing terminal differentiation of osteoblasts in the mouse femur","volume":"36","author":"Nagashima","year":"2005","journal-title":"Bone"},{"key":"10.14219\/jada.archive.2005.0108_bib12","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1359\/JBMR.040326","article-title":"Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension","volume":"19","author":"Ensrud","year":"2004","journal-title":"J Bone Miner Res"},{"key":"10.14219\/jada.archive.2005.0108_bib13","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1210\/jc.2004-0952","article-title":"Severely suppressed bone turnover: a potential complication of alendronate therapy","volume":"90","author":"Odvina","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.14219\/jada.archive.2005.0108_bib14","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1124\/jpet.102.035295","article-title":"Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid","volume":"302","author":"Wood","year":"2002","journal-title":"J Phamacol Exp Ther"},{"key":"10.14219\/jada.archive.2005.0108_bib15","first-page":"6538","article-title":"Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats","volume":"62","author":"Fournier","year":"2002","journal-title":"Cancer Res"},{"key":"10.14219\/jada.archive.2005.0108_bib16","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0889-8529(05)70014-1","article-title":"Treatment of osteoporosis with bisphosphonates","volume":"27","author":"Watts","year":"1998","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.14219\/jada.archive.2005.0108_bib17","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/1097-0142(20010401)91:7<1191::AID-CNCR1119>3.0.CO;2-0","article-title":"Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases","volume":"91","author":"Berenson","year":"2001","journal-title":"Cancer"},{"issue":"6 supplement 1","key":"10.14219\/jada.archive.2005.0108_bib18","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1097\/00000421-200212001-00006","article-title":"Future directions in the treatment and prevention of bone metastases","volume":"25","author":"Coleman","year":"2002","journal-title":"Am J Clin Oncol"},{"key":"10.14219\/jada.archive.2005.0108_bib19","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1470-2045(03)01076-3","article-title":"Aetiology of bone disease and the role of bisphosphonates in multiple myeloma","volume":"4","author":"Ashcroft","year":"2003","journal-title":"Lancet Oncol"},{"key":"10.14219\/jada.archive.2005.0108_bib20","series-title":"Bisphosphonates in bone disease: From the laboratory to the patients","first-page":"34","author":"Fleisch","year":"2000"},{"key":"10.14219\/jada.archive.2005.0108_bib21","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1200\/JCO.2003.08.017","article-title":"American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer [published erratum appears in J Clin Oncol 2004;22(7):1351]","volume":"21","author":"Hillner","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.14219\/jada.archive.2005.0108_bib22","doi-asserted-by":"crossref","first-page":"417","DOI":"10.2165\/00003495-200363040-00009","article-title":"Zoledronic acid: a review of its use in the management of bone metastases and hypercalcemia of malignancy","volume":"63","author":"Wellington","year":"2003","journal-title":"Drugs"},{"key":"10.14219\/jada.archive.2005.0108_bib23","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1634\/theoncologist.10-1-52","article-title":"Recommendations for zoledronic acid treatment of patients with bone metastases","volume":"10","author":"Berenson","year":"2005","journal-title":"Oncologist"},{"key":"10.14219\/jada.archive.2005.0108_bib24","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1359\/jbmr.2001.16.9.1575","article-title":"Cancellous bone remodeling occurs in specialized compartments lined by cells expressing osteoblastic markers","volume":"16","author":"Hauge","year":"2001","journal-title":"J Bone Miner Res"},{"key":"10.14219\/jada.archive.2005.0108_bib25","first-page":"389","article-title":"Antiresorptive dose-dependent relationship across three generations of bisphosphonates","volume":"15","author":"Sietsema","year":"1989","journal-title":"Drugs Exp Clin Res"},{"key":"10.14219\/jada.archive.2005.0108_bib26","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1056\/NEJMoa023110","article-title":"Bisphosphonate-induced osteopetrosis","volume":"349","author":"Whyte","year":"2003","journal-title":"N Engl J Med"},{"key":"10.14219\/jada.archive.2005.0108_bib27","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1056\/NEJMp038103","article-title":"Do bisphosphonates make children's bones better or brittle?","volume":"349","author":"Marini","year":"2003","journal-title":"N Engl J Med"},{"key":"10.14219\/jada.archive.2005.0108_bib28","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.joms.2005.01.010","article-title":"Bisphosphonate osteochemonecrosis (bisphossy jaw): is this phossy jaw of the 21st century?","volume":"63","author":"Hellstein","year":"2005","journal-title":"J Oral Maxillofac Surg"},{"key":"10.14219\/jada.archive.2005.0108_bib29","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/cncr.21130","article-title":"Bisphosphate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy","volume":"104","author":"Migliorati","year":"2005","journal-title":"Cancer"},{"issue":"5 supplement 13","key":"10.14219\/jada.archive.2005.0108_bib30","first-page":"28","article-title":"Novel approaches in myeloma therapy","volume":"26","author":"Munshi","year":"1999","journal-title":"Semin Oncol"},{"key":"10.14219\/jada.archive.2005.0108_bib31","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S1297-319X(03)00018-6","article-title":"Treatment of multiple myeloma","volume":"70","author":"Clerc","year":"2003","journal-title":"Joint Bone Spine"},{"issue":"4 supplement 7","key":"10.14219\/jada.archive.2005.0108_bib32","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1053\/j.seminhematol.2004.09.002","article-title":"New treatment strategies for multiple myeloma","volume":"41","author":"Hussein","year":"2004","journal-title":"Semin Hematol"},{"key":"10.14219\/jada.archive.2005.0108_bib33","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1158\/1535-7163.MCT-04-0338","article-title":"Proteasome inhibitor therapy in multiple myeloma","volume":"4","author":"Chauhan","year":"2005","journal-title":"Mol Cancer Ther"},{"key":"10.14219\/jada.archive.2005.0108_bib34","series-title":"Oral and maxillo-facial pathology: A rationale for diagnosis and treatment","first-page":"36","author":"Marx","year":"2003"},{"key":"10.14219\/jada.archive.2005.0108_bib35","doi-asserted-by":"crossref","first-page":"4253","DOI":"10.1200\/JCO.2003.99.132","article-title":"Bisphosphonates and oral cavity avascular bone necrosis","volume":"21","author":"Migliorati","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.14219\/jada.archive.2005.0108_bib36","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","article-title":"Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic","volume":"61","author":"Marx","year":"2003","journal-title":"J Oral Maxillofac Surg"},{"key":"10.14219\/jada.archive.2005.0108_bib37","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1111\/j.1365-2141.2005.05382.x","article-title":"Osteonecrosis of the jaw associated with zoledronate therapy in a patient with multiple myeloma","volume":"128","author":"Vannucchi","year":"2005","journal-title":"Br J Haematol"},{"key":"10.14219\/jada.archive.2005.0108_bib38","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/S0278-2391(03)00328-8","article-title":"Osteonecrosis of the jaws associated with cancer chemotherapy","volume":"61","author":"Wang","year":"2003","journal-title":"J Oral Maxillofac Surg"},{"key":"10.14219\/jada.archive.2005.0108_bib39","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.joms.2003.11.003","article-title":"Bisphosphonates and bone necrosis","volume":"62","author":"Pogrel","year":"2004","journal-title":"J Oral Maxillofac Surg"},{"key":"10.14219\/jada.archive.2005.0108_bib40","first-page":"750","article-title":"Osteonecrosis of the maxilla and mandible in patients treated with bisphosphonates: a retrospective study (abstract)","volume":"22","author":"Estilo","year":"2004","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.14219\/jada.archive.2005.0108_bib41","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.joms.2004.02.004","article-title":"Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases","volume":"62","author":"Ruggiero","year":"2004","journal-title":"J Oral Maxillofac Surg"},{"key":"10.14219\/jada.archive.2005.0108_bib42","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.amjmed.2004.04.015","article-title":"Severe osteomyelitis of the jaw in long-term survivors of multiple myeloma: a new clinical entity","volume":"117","author":"Lugassy","year":"2004","journal-title":"Am J Med"},{"issue":"11","key":"10.14219\/jada.archive.2005.0108_bib43","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V104.11.4905.4905","article-title":"Oral cavity avascular bone necrosis: a newly recognized complication of intravenous (IV) bisphosphonate therapy in cancer patients (abstract 4905)","volume":"104","author":"Schuster","year":"2004","journal-title":"Blood"},{"issue":"11","key":"10.14219\/jada.archive.2005.0108_bib44","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V104.11.4908.4908","article-title":"Osteonecrosis of the jaw associated with pamidronate therapy (abstract 4908)","volume":"104","author":"Zarychanski","year":"2004","journal-title":"Blood"},{"issue":"11","key":"10.14219\/jada.archive.2005.0108_bib45","article-title":"Bisphosphonate therapy associated with an increased incidence of mandibular\/maxillary osteomyelitis in multiple myeloma patients (abstract 4925)","volume":"104","author":"Takkar","year":"2004","journal-title":"Blood"},{"key":"10.14219\/jada.archive.2005.0108_bib46","first-page":"111","article-title":"Osteonecrosis of the maxilla in a patient with history of bisphosphonate therapy","volume":"71","author":"Melo","year":"2005","journal-title":"J Can Dent Assoc"},{"key":"10.14219\/jada.archive.2005.0108_bib47","doi-asserted-by":"crossref","first-page":"417","DOI":"10.5694\/j.1326-5377.2005.tb06762.x","article-title":"Bisphosphonates and osteonecrosis of the jaw","volume":"182","author":"Purcell","year":"2005","journal-title":"Med J Aust"},{"key":"10.14219\/jada.archive.2005.0108_bib48","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.1600-0714.2004.00269.x","article-title":"Avascular jaw osteonecrosis in association with cancer chemotherapy: series of 10 cases","volume":"34","author":"Bagan","year":"2005","journal-title":"J Oral Pathol Med"},{"issue":"4","key":"10.14219\/jada.archive.2005.0108_bib49","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s10006-005-0616-6","article-title":"Bisphosphonates and osteonecrosis of the jaw [in German]","volume":"9","author":"Schirmer","year":"2005","journal-title":"Mund Kiefer Gesichtschir"},{"issue":"3","key":"10.14219\/jada.archive.2005.0108_bib50","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1188\/05.CJON.355-357","article-title":"Exposed bone in oral cavities","volume":"9","author":"Viale","year":"2005","journal-title":"J Clin Oncol Nursing"},{"key":"10.14219\/jada.archive.2005.0108_bib51","first-page":"100","article-title":"Osteonecrosis of the jaw and bisphosphonates (letter)","volume":"353","author":"Maerevoet","year":"2005","journal-title":"N Engl J Med"},{"issue":"10","key":"10.14219\/jada.archive.2005.0108_bib52","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1097\/01.don.0000182737.09980.2c","article-title":"Bisphosphonate-associated osteonecrosis of the jaws and endodontic treatment: two case reports","volume":"31","author":"Sarathy","year":"2005","journal-title":"J Endod"},{"key":"10.14219\/jada.archive.2005.0108_bib53","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1111\/j.1600-051X.2005.00842.x","article-title":"Osteonecrosis of the jaws in periodontal patients with a history of bisphosphonates treatment","volume":"32","author":"Ficarra","year":"2005","journal-title":"J Clin Periodontol"},{"key":"10.14219\/jada.archive.2005.0108_bib54","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1056\/NEJM200507073530120","article-title":"Osteonecrosis of the jaw and bisphosphonates (letter)","volume":"353","author":"Durie","year":"2005","journal-title":"N Engl J Med"},{"key":"10.14219\/jada.archive.2005.0108_bib55","series-title":"Expert panel recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaws, June 2004: Professional education material","year":"2004"}],"container-title":["The Journal of the American Dental Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002817714624454?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002817714624454?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,13]],"date-time":"2020-08-13T17:15:11Z","timestamp":1597338911000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002817714624454"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,12]]},"references-count":55,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2005,12]]}},"alternative-id":["S0002817714624454"],"URL":"https:\/\/doi.org\/10.14219\/jada.archive.2005.0108","relation":{},"ISSN":["0002-8177"],"issn-type":[{"value":"0002-8177","type":"print"}],"subject":[],"published":{"date-parts":[[2005,12]]}}}